These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7624265)

  • 21. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholestasis associated with mesalazine therapy in a patient with Crohn's disease.
    Stoschus B; Meybehm M; Spengler U; Scheurlen C; Sauerbruch T
    J Hepatol; 1997 Feb; 26(2):425-8. PubMed ID: 9059966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Side effects of 5-aminosalicylic acid].
    Marteau P; Cellier C
    Gastroenterol Clin Biol; 1997; 21(5):377-86. PubMed ID: 9208013
    [No Abstract]   [Full Text] [Related]  

  • 24. [5-ASA versus sulfasalazine].
    Varela E
    Acta Gastroenterol Latinoam; 1994; 25(5):317-9. PubMed ID: 7785405
    [No Abstract]   [Full Text] [Related]  

  • 25. Sulfasalazine desensitization in children and adolescents with chronic inflammatory bowel disease.
    Tolia V
    Am J Gastroenterol; 1992 Aug; 87(8):1029-32. PubMed ID: 1353658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole).
    Hedenmalm K; Spigset O
    Eur J Clin Pharmacol; 2002 Jul; 58(4):265-74. PubMed ID: 12136373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine.
    Hautekeete ML; Bourgeois N; Potvin P; Duville L; Reynaert H; Devis G; Adler M; Klöppel G
    Gastroenterology; 1992 Dec; 103(6):1925-7. PubMed ID: 1360436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mesalazine and sulphasalazine for Crohn's disease: few indications, severe adverse reactions].
    Uittenbogaart SB; Klemt-Kropp M
    Ned Tijdschr Geneeskd; 2011; 155(48):A3842. PubMed ID: 22152414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyperleucocytosis following G-CSF treatment for sulfasalazine-induced agranulocytosis.
    Chan K; Farooq R
    BMJ Case Rep; 2015 Jul; 2015():. PubMed ID: 26178004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A case of ulcerative colitis with mesalazine intolerance complicated with agranulocytosis and septic shock during salazosulfapyridine administration].
    Ikehata A; Honta S; Sekino Y; Masuo T; Eizuka K; Inomata N; Ono S
    Nihon Shokakibyo Gakkai Zasshi; 2023; 120(9):764-772. PubMed ID: 37690832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-induced blood disorders.
    Danielson DA; Douglas SW; Herzog P; Jick H; Porter JB
    JAMA; 1984 Dec; 252(23):3257-60. PubMed ID: 6151006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
    Baker DE; Kane S
    Rev Gastroenterol Disord; 2004; 4(2):86-91. PubMed ID: 15185719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pentasa (mesalazine) and pregnancy].
    Jonville-Bera AP; Soyez C; Fignon A; Moraine C; Berger C; Autret E
    Therapie; 1994; 49(5):443-5. PubMed ID: 7855761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy and tolerability of 5-aminosalicylic acid in the short-term treatment of ulcerative rectocolitis during the mild or moderate stage].
    Bresci G; Carrai M; Venturini G; Gambardella L
    Minerva Dietol Gastroenterol; 1990; 36(1):31-3. PubMed ID: 1970855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mesalamine intolerance mimics symptoms of active inflammatory bowel disease.
    Iofel E; Chawla A; Daum F; Markowitz J
    J Pediatr Gastroenterol Nutr; 2002 Jan; 34(1):73-6. PubMed ID: 11753169
    [No Abstract]   [Full Text] [Related]  

  • 36. [Thrombopenia during 5-ASA treatment (mesalazine and olsalazine)].
    Benoit R; Grobost O; Bichoffe A; Dol L
    Gastroenterol Clin Biol; 1999 Mar; 23(3):410-1. PubMed ID: 10384350
    [No Abstract]   [Full Text] [Related]  

  • 37. [The treatment of inflammatory intestinal diseases with preparations of 5-aminosalicylic acid].
    Frol'kis AV
    Ter Arkh; 1996; 68(2):75-7. PubMed ID: 8771669
    [No Abstract]   [Full Text] [Related]  

  • 38. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis.
    Munakata A; Yoshida Y; Muto T; Tsuchiya S; Fukushima T; Hiwatashi N; Kobayashi K; Kitano A; Shimoyama T; Inoue M
    J Gastroenterol; 1995 Nov; 30 Suppl 8():108-11. PubMed ID: 8563868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammatory bowel disease.
    Van Rosendaal GM
    CMAJ; 1989 Jul; 141(2):113-23; discussion 123-4. PubMed ID: 2568163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Desensitization to sulfasalazine.
    Hessemer CA; Schinagl EF
    Am J Gastroenterol; 1993 Mar; 88(3):460-1, 462. PubMed ID: 8094941
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.